Targeting the NLRP3 Inflammasome in Atherosclerosis: Advances in Anti-Inflammatory Therapies With Bioactive Natural Products - PubMed
5 hours ago
- #NLRP3 inflammasome
- #natural products
- #atherosclerosis
- Atherosclerosis (AS) is a key pathological factor in cardiovascular and cerebrovascular diseases.
- The traditional cholesterol-centered model is insufficient, leading to a combined anti-inflammatory and lipid-lowering strategy.
- The NLRP3 inflammasome is a critical target in AS due to its role in integrating pro-atherogenic signals.
- No FDA-approved NLRP3-targeting agents currently exist, highlighting an unmet clinical need.
- Natural products are promising for AS treatment due to their safety and multi-target effects.
- This review evaluates natural products targeting NLRP3 inflammasome-related pathways in AS.
- Large-scale, high-quality randomized controlled trials are needed to confirm efficacy and safety.